Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Translational Medicine
Published in: Journal of Translational Medicine 1/2008

Open Access 01-12-2008 | Research

NCX-4040, a nitric oxide-releasing aspirin, sensitizes drug-resistant human ovarian xenograft tumors to cisplatin by depletion of cellular thiols

Authors: Anna Bratasz, Karuppaiyah Selvendiran, Tomasz Wasowicz, Andrey Bobko, Valery V Khramtsov, Louis J Ignarro, Periannan Kuppusamy

Published in: Journal of Translational Medicine | Issue 1/2008

Login to get access

Abstract

Background

Ovarian carcinoma is the leading cause of mortality among gynecological cancers in the world. The high mortality rate is associated with lack of early diagnosis and development of drug resistance. The antitumor efficacy and mechanism of NCX-4040, a nitric oxide-releasing aspirin derivative, against ovarian cancer is studied.

Methods

NCX-4040, alone or in combination with cisplatin (cis-diamminedichloroplatinum, cDDP), was studied in cisplatin-sensitive (A2780 WT) and cisplatin-resistant (A2780 cDDP) cell lines as well as xenograft tumors grown in nude mice. Electron paramagnetic resonance (EPR) was used for measurements of nitric oxide and redox state. Immunoblotting analysis of A2780 cDDP tumor xenografts from mice was used for mechanistic studies.

Results

Cells treated with NCX-4040 (25 μM) showed a significant reduction of cell viability (A2780 WT, 34.9 ± 8.7%; A2780 cDDP, 41.7 ± 7.6%; p < 0.05). Further, NCX-4040 significantly enhanced the sensitivity of A2780 cDDP cells (cisplatin alone, 80.6 ± 11.8% versus NCX-4040+cisplatin, 26.4 ± 7.6%; p < 0.01) and xenograft tumors (cisplatin alone, 74.0 ± 4.4% versus NCX-4040+cisplatin, 56.4 ± 7.8%; p < 0.05), to cisplatin treatment. EPR imaging of tissue redox and thiol measurements showed a 5.5-fold reduction (p < 0.01) of glutathione in NCX-4040-treated A2780 cDDP tumors when compared to untreated controls. Immunoblotting analysis of A2780 cDDP tumor xenografts from mice treated with NCX-4040 and cisplatin revealed significant downregulation of pEGFR (Tyr845 and Tyr992) and pSTAT3 (Tyr705 and Ser727) expression.

Conclusion

The results suggested that NCX-4040 could resensitize drug-resistant ovarian cancer cells to cisplatin possibly by depletion of cellular thiols. Thus NCX-4040 appears to be a potential therapeutic agent for the treatment of human ovarian carcinoma and cisplatin-resistant malignancies.
Appendix
Available only for authorised users
Literature
1.
Harries M, Gore M: Part I: chemotherapy for epithelial ovarian cancer-treatment at first diagnosis. Lancet Oncol. 2002, 3 (9): 529-536. 10.1016/S1470-2045(02)00846-X.CrossRefPubMed
2.
Harries M, Gore M: Part II: chemotherapy for epithelial ovarian cancer-treatment of recurrent disease. Lancet Oncol. 2002, 3 (9): 537-545. 10.1016/S1470-2045(02)00847-1.CrossRefPubMed
3.
Yao X, Panichpisal K, Kurtzman N, Nugent K: Cisplatin nephrotoxicity: a review. Am J Med Sci. 2007, 334 (2): 115-124. 10.1097/MAJ.0b013e31812dfe1e.CrossRefPubMed
4.
Screnci D, McKeage MJ: Platinum neurotoxicity: clinical profiles, experimental models and neuroprotective approaches. J Inorg Biochem. 1999, 77 (1-2): 105-110. 10.1016/S0162-0134(99)00135-X.CrossRefPubMed
5.
Rybak LP, Whitworth CA, Mukherjea D, Ramkumar V: Mechanisms of cisplatin-induced ototoxicity and prevention. Hear Res. 2007, 226 (1-2): 157-167. 10.1016/j.heares.2006.09.015.CrossRefPubMed
6.
Guastalla JP, Dieras V: The taxanes: toxicity and quality of life considerations in advanced ovarian cancer. Br J Cancer. 2003, 89 Suppl 3: S16-22. 10.1038/sj.bjc.6601496.CrossRefPubMed
7.
Johnson SW, Ozols RF, Hamilton TC: Mechanisms of drug resistance in ovarian cancer. Cancer. 1993, 71 (2 Suppl): 644-649.PubMed
8.
Kartalou M, Essigmann JM: Mechanisms of resistance to cisplatin. Mutat Res. 2001, 478 (1-2): 23-43.CrossRefPubMed
9.
Agarwal R, Kaye SB: Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer. 2003, 3 (7): 502-516. 10.1038/nrc1123.CrossRefPubMed
10.
Eastman A: Cross-linking of glutathione to DNA by cancer chemotherapeutic platinum coordination complexes. Chem Biol Interact. 1987, 61 (3): 241-248. 10.1016/0009-2797(87)90004-4.CrossRefPubMed
11.
Ishikawa T: The ATP-dependent glutathione S-conjugate export pump. Trends Biochem Sci. 1992, 17 (11): 463-468. 10.1016/0968-0004(92)90489-V.CrossRefPubMed
12.
Rabik CA, Dolan ME: Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev. 2007, 33 (1): 9-23. 10.1016/j.ctrv.2006.09.006.PubMedCentralCrossRefPubMed
13.
Kelland L: The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer. 2007, 7 (8): 573-584. 10.1038/nrc2167.CrossRefPubMed
14.
Lewandowicz GM, Britt P, Elgie AW, Williamson CJ, Coley HM, Hall AG, Sargent JM: Cellular glutathione content, in vitro chemoresponse, and the effect of BSO modulation in samples derived from patients with advanced ovarian cancer. Gynecologic oncology. 2002, 85 (2): 298-304. 10.1006/gyno.2002.6617.CrossRefPubMed
15.
Liebmann JE, Hahn SM, Cook JA, Lipschultz C, Mitchell JB, Kaufman DC: Glutathione depletion by L-buthionine sulfoximine antagonizes taxol cytotoxicity. Cancer Res. 1993, 53 (9): 2066-2070.PubMed
16.
Rudin CM, Yang Z, Schumaker LM, VanderWeele DJ, Newkirk K, Egorin MJ, Zuhowski EG, Cullen KJ: Inhibition of glutathione synthesis reverses Bcl-2-mediated cisplatin resistance. Cancer Res. 2003, 63 (2): 312-318.PubMed
17.
Schnelldorfer T, Gansauge S, Gansauge F, Schlosser S, Beger HG, Nussler AK: Glutathione depletion causes cell growth inhibition and enhanced apoptosis in pancreatic cancer cells. Cancer. 2000, 89 (7): 1440-1447. 10.1002/1097-0142(20001001)89:7<1440::AID-CNCR5>3.0.CO;2-0.CrossRefPubMed
18.
Bratasz A, Weir NM, Parinandi NL, Zweier JL, Sridhar R, Ignarro LJ, Kuppusamy P: Reversal to cisplatin sensitivity in recurrent human ovarian cancer cells by NCX-4016, a nitro derivative of aspirin. Proc Natl Acad Sci U S A. 2006, 103 (10): 3914-3919. 10.1073/pnas.0511250103.PubMedCentralCrossRefPubMed
19.
Selvendiran K, Bratasz A, Tong L, Ignarro LJ, Kuppusamy P: NCX-4016, a nitro-derivative of aspirin, inhibits EGFR and STAT3 signaling and modulates Bcl-2 proteins in cisplatin-resistant human ovarian cancer cells and xenografts. Cell Cycle. 2008, 7 (1): 81-88.PubMedCentralCrossRefPubMed
20.
Gao J, Kashfi K, Rigas B: In vitro metabolism of nitric oxide-donating aspirin: the effect of positional isomerism. J Pharmacol Exp Ther. 2005, 312 (3): 989-997. 10.1124/jpet.104.076190.CrossRefPubMed
21.
Rosetti M, Tesei A, Ulivi P, Fabbri F, Vannini I, Brigliadori G, Amadori D, Bolla M, Zoli W: Molecular characterization of cytotoxic and resistance mechanisms induced by NCX 4040, a novel NO-NSAID, in pancreatic cancer cell lines. Apoptosis. 2006, 11 (8): 1321-1330. 10.1007/s10495-006-6986-x.CrossRefPubMed
22.
Fabbri F, Brigliadori G, Ulivi P, Tesei A, Vannini I, Rosetti M, Bravaccini S, Amadori D, Bolla M, Zoli W: Pro-apoptotic effect of a nitric oxide-donating NSAID, NCX 4040, on bladder carcinoma cells. Apoptosis. 2005, 10 (5): 1095-1103. 10.1007/s10495-005-0619-7.CrossRefPubMed
23.
Leonetti C, Scarsella M, Zupi G, Zoli W, Amadori D, Medri L, Fabbri F, Rosetti M, Ulivi P, Cecconetto L, Bolla M, Tesei A: Efficacy of a nitric oxide-releasing nonsteroidal anti-inflammatory drug and cytotoxic drugs in human colon cancer cell lines in vitro and xenografts. Mol Cancer Ther. 2006, 5 (4): 919-926. 10.1158/1535-7163.MCT-05-0536.CrossRefPubMed
24.
Tesei A, Ulivi P, Fabbri F, Rosetti M, Leonetti C, Scarsella M, Zupi G, Amadori D, Bolla M, Zoli W: In vitro and in vivo evaluation of NCX 4040 cytotoxic activity in human colon cancer cell lines. J Transl Med. 2005, 3 (1): 7-10.1186/1479-5876-3-7.PubMedCentralCrossRefPubMed
25.
Tesei A, Rosetti M, Ulivi P, Fabbri F, Medri L, Vannini I, Bolla M, Amadori D, Zoli W: Study of molecular mechanisms of pro-apoptotic activity of NCX 4040, a novel nitric oxide-releasing aspirin, in colon cancer cell lines. J Transl Med. 2007, 5 (1): 52-10.1186/1479-5876-5-52.PubMedCentralCrossRefPubMed
26.
Kashfi K, Borgo S, Williams JL, Chen J, Gao J, Glekas A, Benedini F, Del Soldato P, Rigas B: Positional isomerism markedly affects the growth inhibition of colon cancer cells by nitric oxide-donating aspirin in vitro and in vivo. J Pharmacol Exp Ther. 2005, 312 (3): 978-988. 10.1124/jpet.104.075994.CrossRefPubMed
27.
Khramtsov VV, Yelinova VI, Glazachev Yu I, Reznikov VA, Zimmer G: Quantitative determination and reversible modification of thiols using imidazolidine biradical disulfide label. J Biochem Biophys Methods. 1997, 35 (2): 115-128. 10.1016/S0165-022X(97)00035-3.CrossRefPubMed
28.
Kuppusamy P, Wang P, Samouilov A, Zweier JL: Spatial mapping of nitric oxide generation in the ischemic heart using electron paramagnetic resonance imaging. Magn Reson Med. 1996, 36 (2): 212-218. 10.1002/mrm.1910360207.CrossRefPubMed
29.
Andrews PA, Jones JA, Varki NM, Howell SB: Rapid emergence of acquired cis-diamminedichloroplatinum(II) resistance in an in vivo model of human ovarian carcinoma. Cancer communications. 1990, 2 (2): 93-100.PubMed
30.
Kern DH, Morgan CR, Hildebrand-Zanki SU: In vitro pharmacodynamics of 1-beta-D-arabinofuranosylcytosine: synergy of antitumor activity with cis-diamminedichloroplatinum(II). Cancer Res. 1988, 48 (1): 117-121.PubMed
31.
Khramtsov VV, Yelinova VI, Weiner LM, Berezina TA, Martin VV, Volodarsky LB: Quantitative determination of SH groups in low- and high-molecular-weight compounds by an electron spin resonance method. Anal Biochem. 1989, 182 (1): 58-63. 10.1016/0003-2697(89)90718-5.CrossRefPubMed
32.
Kuppusamy P, Afeworki M, Shankar RA, Coffin D, Krishna MC, Hahn SM, Mitchell JB, Zweier JL: In vivo electron paramagnetic resonance imaging of tumor heterogeneity and oxygenation in a murine model. Cancer Res. 1998, 58 (7): 1562-1568.PubMed
33.
Ilangovan G, Bratasz A, Li H, Schmalbrock P, Zweier JL, Kuppusamy P: In vivo measurement and imaging of tumor oxygenation using coembedded paramagnetic particulates. Magn Reson Med. 2004, 52 (3): 650-657. 10.1002/mrm.20188.CrossRefPubMed
34.
Komarov A, Mattson D, Jones MM, Singh PK, Lai CS: In vivo spin trapping of nitric oxide in mice. Biochem Biophys Res Commun. 1993, 195 (3): 1191-1198. 10.1006/bbrc.1993.2170.CrossRefPubMed
35.
Kuppusamy P, Li H, Ilangovan G, Cardounel AJ, Zweier JL, Yamada K, Krishna MC, Mitchell JB: Noninvasive imaging of tumor redox status and its modification by tissue glutathione levels. Cancer Res. 2002, 62 (1): 307-312.PubMed
36.
del Soldato P, Sorrentino R, Pinto A: NO-aspirins: a class of new anti-inflammatory and antithrombotic agents. Trends Pharmacol Sci. 1999, 20 (8): 319-323. 10.1016/S0165-6147(99)01353-X.CrossRefPubMed
37.
Cohen SM, Lippard SJ: Cisplatin: from DNA damage to cancer chemotherapy. Prog Nucleic Acid Res Mol Biol. 2001, 67: 93-130.CrossRefPubMed
38.
Nishimura T, Newkirk K, Sessions RB, Andrews PA, Trock BJ, Rasmussen AA, Montgomery EA, Bischoff EK, Cullen KJ: Immunohistochemical staining for glutathione S-transferase predicts response to platinum-based chemotherapy in head and neck cancer. Clin Cancer Res. 1996, 2 (11): 1859-1865.PubMed
39.
Shiga H, Heath EI, Rasmussen AA, Trock B, Johnston PG, Forastiere AA, Langmacher M, Baylor A, Lee M, Cullen KJ: Prognostic value of p53, glutathione S-transferase pi, and thymidylate synthase for neoadjuvant cisplatin-based chemotherapy in head and neck cancer. Clin Cancer Res. 1999, 5 (12): 4097-4104.PubMed
40.
Nishimura T, Newkirk K, Sessions RB, Andrews PA, Trock BJ, Rusmussen AA, Montogomery EA, Bischoff EK, Hanigan MH, Cullen KJ: Association between expression of glutathione-associated enzymes and response to platinum-based chemotherapy in head and neck cancer. Chem Biol Interact. 1998, 111-112: 187-198. 10.1016/S0009-2797(97)00161-0.CrossRefPubMed
41.
Hockenbery DM, Oltvai ZN, Yin XM, Milliman CL, Korsmeyer SJ: Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell. 1993, 75 (2): 241-251. 10.1016/0092-8674(93)80066-N.CrossRefPubMed
42.
Clancy RM, Levartovsky D, Leszczynska-Piziak J, Yegudin J, Abramson SB: Nitric oxide reacts with intracellular glutathione and activates the hexose monophosphate shunt in human neutrophils: evidence for S-nitrosoglutathione as a bioactive intermediary. Proc Natl Acad Sci U S A. 1994, 91 (9): 3680-3684. 10.1073/pnas.91.9.3680.PubMedCentralCrossRefPubMed
43.
Clark AG, Debnam P: Inhibition of glutathione S-transferases from rat liver by S-nitroso-L-glutathione. Biochem Pharmacol. 1988, 37 (16): 3199-3201. 10.1016/0006-2952(88)90321-8.CrossRefPubMed
44.
Becker K, Gui M, Schirmer RH: Inhibition of human glutathione reductase by S-nitrosoglutathione. Eur J Biochem. 1995, 234 (2): 472-478. 10.1111/j.1432-1033.1995.472_b.x.CrossRefPubMed
45.
Hulsman N, Medema JP, Bos C, Jongejan A, Leurs R, Smit MJ, de Esch IJ, Richel D, Wijtmans M: Chemical insights in the concept of hybrid drugs: the antitumor effect of nitric oxide-donating aspirin involves a quinone methide but not nitric oxide nor aspirin. J Med Chem. 2007, 50 (10): 2424-2431. 10.1021/jm061371e.CrossRefPubMed
46.
Kashfi K, Rigas B: The mechanism of action of nitric oxide-donating aspirin. Biochem Biophys Res Commun. 2007, 358 (4): 1096-1101. 10.1016/j.bbrc.2007.05.038.CrossRefPubMed
47.
Dunlap T, Chandrasena RE, Wang Z, Sinha V, Wang Z, Thatcher GR: Quinone formation as a chemoprevention strategy for hybrid drugs: balancing cytotoxicity and cytoprotection. Chem Res Toxicol. 2007, 20 (12): 1903-1912. 10.1021/tx7002257.CrossRefPubMed
48.
Salomon DS, Brandt R, Ciardiello F, Normanno N: Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol. 1995, 19 (3): 183-232. 10.1016/1040-8428(94)00144-I.CrossRefPubMed
49.
Coley HM, Shotton CF, Ajose-Adeogun A, Modjtahedi H, Thomas H: Receptor tyrosine kinase (RTK) inhibition is effective in chemosensitising EGFR-expressing drug resistant human ovarian cancer cell lines when used in combination with cytotoxic agents. Biochem Pharmacol. 2006, 72 (8): 941-948. 10.1016/j.bcp.2006.07.022.CrossRefPubMed
50.
Woodworth CD, Michael E, Marker D, Allen S, Smith L, Nees M: Inhibition of the epidermal growth factor receptor increases expression of genes that stimulate inflammation, apoptosis, and cell attachment. Mol Cancer Ther. 2005, 4 (4): 650-658. 10.1158/1535-7163.MCT-04-0238.CrossRefPubMed
51.
Duan Z, Foster R, Bell DA, Mahoney J, Wolak K, Vaidya A, Hampel C, Lee H, Seiden MV: Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer. Clin Cancer Res. 2006, 12 (17): 5055-5063. 10.1158/1078-0432.CCR-06-0861.CrossRefPubMed
52.
Lo HW, Hsu SC, Ali-Seyed M, Gunduz M, Xia W, Wei Y, Bartholomeusz G, Shih JY, Hung MC: Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway. Cancer Cell. 2005, 7 (6): 575-589. 10.1016/j.ccr.2005.05.007.CrossRefPubMed
53.
Bhardwaj A, Sethi G, Vadhan-Raj S, Bueso-Ramos C, Takada Y, Gaur U, Nair AS, Shishodia S, Aggarwal BB: Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-kappaB-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells. Blood. 2007, 109 (6): 2293-2302. 10.1182/blood-2006-02-003988.CrossRefPubMed
54.
Choudhari SR, Khan MA, Harris G, Picker D, Jacob GS, Block T, Shailubhai K: Deactivation of Akt and STAT3 signaling promotes apoptosis, inhibits proliferation, and enhances the sensitivity of hepatocellular carcinoma cells to an anticancer agent, Atiprimod. Mol Cancer Ther. 2007, 6 (1): 112-121. 10.1158/1535-7163.MCT-06-0561.CrossRefPubMed
55.
Selvendiran K, Koga H, Ueno T, Yoshida T, Maeyama M, Torimura T, Yano H, Kojiro M, Sata M: Luteolin promotes degradation in signal transducer and activator of transcription 3 in human hepatoma cells: an implication for the antitumor potential of flavonoids. Cancer Res. 2006, 66 (9): 4826-4834. 10.1158/0008-5472.CAN-05-4062.CrossRefPubMed
56.
Torroglosa A, Murillo-Carretero M, Romero-Grimaldi C, Matarredona ER, Campos-Caro A, Estrada C: Nitric oxide decreases subventricular zone stem cell proliferation by inhibition of epidermal growth factor receptor and phosphoinositide-3-kinase/Akt pathway. Stem cells (Dayton, Ohio). 2007, 25 (1): 88-97. 10.1634/stemcells.2006-0131.CrossRef
57.
Rieder J, Jahnke R, Schloesser M, Seibel M, Czechowski M, Marth C, Hoffmann G: Nitric oxide-dependent apoptosis in ovarian carcinoma cell lines. Gynecologic oncology. 2001, 82 (1): 172-176. 10.1006/gyno.2001.6242.CrossRefPubMed
58.
Yu H, Jove R: The STATs of cancer--new molecular targets come of age. Nat Rev Cancer. 2004, 4 (2): 97-105.CrossRefPubMed
Metadata
Title
NCX-4040, a nitric oxide-releasing aspirin, sensitizes drug-resistant human ovarian xenograft tumors to cisplatin by depletion of cellular thiols
Authors
Anna Bratasz
Karuppaiyah Selvendiran
Tomasz Wasowicz
Andrey Bobko
Valery V Khramtsov
Louis J Ignarro
Periannan Kuppusamy
Publication date
01-12-2008
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2008
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/1479-5876-6-9

Other articles of this Issue 1/2008

Journal of Translational Medicine 1/2008 Go to the issue

Research

In vitro generation of cytotoxic and regulatory T cells by fusions of human dendritic cells and hepatocellular carcinoma cells

Research

Zoledronic acid increases docetaxel cytotoxicity through pMEK and Mcl-1 inhibition in a hormone-sensitive prostate carcinoma cell line

Research

Whole genome expression and biochemical correlates of extreme constitutional types defined in Ayurveda

Research

Anti-angiogenic effect of high doses of ascorbic acid

Research

Interdependency of CEACAM-1, -3, -6, and -8 induced human neutrophil adhesion to endothelial cells

Commentary

Translational medicine: science or wishful thinking?
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits